<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397771</url>
  </required_header>
  <id_info>
    <org_study_id>IXA-CSP-002</org_study_id>
    <nct_id>NCT03397771</nct_id>
  </id_info>
  <brief_title>DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence</brief_title>
  <official_title>A Double-Blind Randomised Placebo-Controlled Phase I/IIa Dose Titration Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine up to 30 mg vs Placebo BID in Subjects With Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ixaltis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ixaltis SA</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the safety, tolerability and efficacy of litoxetine in men and women
      who suffer from urinary incontinence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind randomized placebo controlled study which will explore the safety,
      tolerability and efficacy of oral litoxetine, a highly selective SSRI, provided by dose
      titration to subjects suffering from urinary incontinence
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Actual">May 30, 2019</completion_date>
  <primary_completion_date type="Actual">May 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind placebo control</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Treatment-Emergent Adverse Events</measure>
    <time_frame>from randomisation to treatment completion, an average of 8 weeks</time_frame>
    <description>AE, SAE, AE of special interest occuring after the start of treatment (LTX or PBP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect Evaluation of Litoxetine for the Treatment of Urinary Incontinence</measure>
    <time_frame>change in number of incontinence episodes from baseline to week 8 of treatment</time_frame>
    <description>number of incontinence episodes measured by the use of a bladder diary; change from baseline to week 8 (the higher the number the worse the incontinence severity; minimum value would be zero, there is no limit for maximum value)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Litoxetine oral capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral experimental study medication litoxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Litoxetine</intervention_name>
    <description>oral study medication provided in a dose titration manner</description>
    <arm_group_label>Litoxetine oral capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo medication provided in a dose titration manner</description>
    <arm_group_label>Placebo oral capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects aged 18 to 70 will be eligible for inclusion in this study if all of the
        following criteria apply:

          1. Willing to provide written informed consent

          2. Have symptoms of urinary incontinence for at least 3 consecutive months

          3. For male subjects: Undergone prostatectomy at least 6 months prior to inclusion

          4. Have at least 7 incontinence episodes per week in the diary entries for the Screening
             Placebo Run In Period

          5. Subject is ambulatory and able to use the toilet independently

          6. If subjects use pelvic floor exercises, subjects must have been on a stable exercise
             and activity regime for at least 3 months prior to screening and that regime must
             remain stable during the treatment period

          7. Subject has a body mass index (BMI) ≥ 19 kg/m2 but ≤ 35 kg/m2 BMI=weight [kg] / height
             [m2}

          8. Subjects must have a pre-dose mean systolic/diastolic blood pressure of ≤ 140/90 mmHg
             before randomization can occur

          9. For female subjects: Must not be pregnant, lactating, or actively trying to become
             pregnant, Subjects who are premenopausal and of childbearing potential must have a
             negative pregnancy test at Screening (serum) and at Day 0 (urine) and must use a
             medically acceptable and effective method of birth control for the duration of the
             study, which can include:

               1. Having a male partner who is sterile prior to the female subject's entry into the
                  study and is the sole sexual partner for that female subject

               2. Use of double-barrier methods of contraception; condoms with the use of caps
                  (with spermicide) and intra-uterine devices are acceptable

               3. Use of hormonal contraceptives (oral, depots, patches, etc.) with double-barrier
                  methods of contraception as outlined above

               4. True abstinence: When this is in line with the preferred and usual lifestyle of
                  the subject (period abstinence [eg, calendar, ovulation, symptothermal,
                  post-ovulation methods] and withdrawal are not acceptable methods of
                  contraception)

         10. Subjects taking oral contraceptives or hormone replacement therapy (women) or hormone
             adjuvant therapy (men) must have a stable dose and regimen for ≥ 3 months prior to
             entry into the study

        Exclusion Criteria:

        A subject will not be eligible to participate in the study if they meet any of the
        following criteria:

          1. History of anti-incontinence surgery in past 12 months

          2. Use of Botox for the treatment of urinary incontinence in the past 12 months

          3. Current or recent (3 months) use of any pharmacologic agent used to treat symptoms of
             urinary incontinence

          4. For women: Grade III/IV pelvic organ prolapse; defined per clinical practice

          5. For women: History of pelvic prolapse repair or urethral diverticulectomy within 12
             months of Screening.

             For men: urethral surgery within 6 months of Screening

          6. History of interstitial cystitis or bladder-related pain

          7. Subjects with concurrent (at Screening), recent (within 30 days), chronic, or
             recurrent (&gt; 4 per year) urinary tract infections (positive dipstick for urinary tract
             infection and abnormal microscopic evaluation, signs and symptoms) or unevaluated
             microhematuria

          8. History of diagnosed gastrointestinal obstructive disorders

          9. Chronic severe constipation

         10. History of radiation cystitis or history of pelvic irradiation

         11. Electrostimulation, biofeedback, or bladder training therapy (behavioural therapy),
             during the previous month prior to Screening, or the intention to initiate such
             therapies during the study period. Pessaries and implants are also excluded.

         12. Postvoid residual (PVR) urine volume &gt; 150 mL

         13. Diagnosis of dementia

         14. Diagnosis of epilepsy

         15. Diagnosis of acute narrow-angle glaucoma

         16. History of mania or diagnosis of bipolar disorder and/or seizures

         17. Subjects with uncontrolled hypertension

         18. Documented history of myocardial infarction, unstable angina, and/or has undergone
             coronary artery bypass surgery and/or percutaneous transluminal coronary angioplasty
             in the past year

         19. Congestive heart failure (New York Heart Association Class III or IV heart failure;
             Appendix 3)

         20. Any concurrent condition or any clinically significant abnormality on the Screening
             physical examination, laboratory tests, electrocardiogram (ECG; including ischemic
             heart disease), Hepatitis B or C, which, in the opinion of the Investigator, may
             affect the interpretation of safety or efficacy data, or which otherwise
             contraindicates participation in a clinical study with litoxetine:

               1. Hypersensitivity to litoxetine or any of its ingredients

               2. History of clinically significant drug hypersensitivity

               3. Subjects with current (within 2 years) urogenital neoplasms or malignancies
                  including bladder, uterine or cervical cancer (not applicable to male subjects
                  with prostate cancer in whom a prostatectomy has been performed)

               4. Subjects with neuropathology that could affect the lower urinary tract or nerve
                  supply, including but not limited to multiple sclerosis, stroke, Parkinsonism, or
                  spinal cord injury

               5. Subjects with diabetes insipidus

               6. Clinically significant or unstable, endocrine, hepatic, renal, immunologic, or
                  lung disease (ie, active chronic obstructive pulmonary disease), or malignancy
                  other than non-melanomatous skin cancer

         21. Severe renal impairment (estimated glomerular filtration rate &lt; 30 mL/min/1.73m2)

         22. Severe hepatic impairment (Child-Pugh B or greater)

         23. Current or recent (6 months) treatment for depression, or a current diagnosis of
             depression or have a state of depression or suicidality at Screening.

         24. History of current or recent (6 months) suicidal ideation and behaviour (SIB), or
             history of any suicide attempt in the past 12 months.

         25. History of an addiction to drugs or alcohol within 5 years prior to screening, or of
             alcohol or substance abuse within the past year, as determined by the Investigator.
             26. Current use of the following medications:, any serotonergic medication,
             nonselective irreversible monoamineoxidase inhibitors (MAOIs), cytochrome P450
             (CYP)1A2 inhibitors (such as fluvoxamine, ciprofloxacin, or enoxacin), cytochrome P450
             (CYP) 2D6 inhibitors (bupropion, fluoxetine, metoclopromide, paroxetine, quinidine),
             pimozide and thioridazine, and any other medication that would be considered a safety
             risk for co-administration with litoxetine (See Section 5.7.2 Prohibited Medications)

        27. Participation in a clinical study within the month prior to Screening, or exposure to
        an investigational drug which has not washed out for at least 5 half-lives since its last
        administration, prior to Screening.

        28. In the opinion of the Investigator, is at risk of non-compliance with study procedures,
        or cannot read, understand, or complete study-related materials (including electronic
        diaries), particularly informed consent.

        29. Participation in any clinical study of an investigational drug that may affect urinary
        function within 3 months prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E Svanberg</last_name>
    <role>Study Director</role>
    <affiliation>Ixaltis SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates LLC</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <results_first_submitted>May 6, 2020</results_first_submitted>
  <results_first_submitted_qc>May 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2020</results_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urinary incontinence, SSRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03397771/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03397771/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects entered the 2 week Run-in Period and received subject blind placebo treatment. Subjects who continued to meet eligibility criteria at the end of the Run-in Period (at least 7 incontinence episodes per week in the diary entries), entered the Treatment Period, randomly assigned (2:1) to receive study drug (litoxetine) for placebo BID.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Litoxetine Oral Capsules</title>
          <description>oral experimental study medication litoxetine
Litoxetine: oral study medication provided in a dose titration manner</description>
        </group>
        <group group_id="P2">
          <title>Placebo Oral Capsules</title>
          <description>oral comparator
placebo: placebo medication provided in a dose titration manner</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>2 erroneously randomized, never treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Litoxetine Oral Capsules</title>
          <description>oral experimental study medication litoxetine
Litoxetine: oral study medication provided in a dose titration manner</description>
        </group>
        <group group_id="B2">
          <title>Placebo Oral Capsules</title>
          <description>oral comparator
placebo: placebo medication provided in a dose titration manner</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Treatment-Emergent Adverse Events</title>
        <description>AE, SAE, AE of special interest occuring after the start of treatment (LTX or PBP)</description>
        <time_frame>from randomisation to treatment completion, an average of 8 weeks</time_frame>
        <population>The analysis of TEAE was conducted on the Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Litoxetine Oral Capsules</title>
            <description>oral experimental study medication litoxetine
Litoxetine: oral study medication provided in a dose titration manner</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsules</title>
            <description>oral comparator
placebo: placebo medication provided in a dose titration manner</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-Emergent Adverse Events</title>
          <description>AE, SAE, AE of special interest occuring after the start of treatment (LTX or PBP)</description>
          <population>The analysis of TEAE was conducted on the Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.963</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect Evaluation of Litoxetine for the Treatment of Urinary Incontinence</title>
        <description>number of incontinence episodes measured by the use of a bladder diary; change from baseline to week 8 (the higher the number the worse the incontinence severity; minimum value would be zero, there is no limit for maximum value)</description>
        <time_frame>change in number of incontinence episodes from baseline to week 8 of treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Litoxetine Oral Capsules</title>
            <description>oral experimental study medication litoxetine
Litoxetine: oral study medication provided in a dose titration manner</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsules</title>
            <description>oral comparator
placebo: placebo medication provided in a dose titration manner</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Evaluation of Litoxetine for the Treatment of Urinary Incontinence</title>
          <description>number of incontinence episodes measured by the use of a bladder diary; change from baseline to week 8 (the higher the number the worse the incontinence severity; minimum value would be zero, there is no limit for maximum value)</description>
          <population>ITT</population>
          <units>incontinence events</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" lower_limit="-2.57" upper_limit="-1.54"/>
                    <measurement group_id="O2" value="-1.20" lower_limit="-1.81" upper_limit="-0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The analysis was conducted according to the nul hypothesis, assuming no difference between treatment arms</non_inferiority_desc>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs were recorded from randomization and through study completion, an average of 8 weeks</time_frame>
      <desc>The AEs reported refer to TEAEs, ie those AE which occurred after starting randomised treatment and going through week 8 of study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Litoxetine Oral Capsules</title>
          <description>oral experimental study medication litoxetine
Litoxetine: oral study medication provided in a dose titration manner</description>
        </group>
        <group group_id="E2">
          <title>Placebo Oral Capsules</title>
          <description>oral comparator
placebo: placebo medication provided in a dose titration manner</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Development Officer</name_or_title>
      <organization>Ixaltis</organization>
      <phone>33457260076</phone>
      <email>svanberg@ixaltis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

